Prospects in Folate Receptor-Targeted Radionuclide Therapy
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 249
Abstract
Targeted radionuclide therapy is based on systemic application of particle-emitting radiopharmaceuticals which are directed towards a specific tumor-associated target. Accumulation of the radiopharmaceutical in targeted cancer cells results in high doses of absorbed radiation energy whereas toxicity to non-targeted healthy tissue is limited. This strategy has found widespread application in the palliative treatment of neuroendocrine tumors using somatostatin-based radiopeptides. The folate receptor (FR) has been identified as a target associated with a variety of frequent tumor types (e.g. ovarian, lung, brain, renal and colorectal cancer). In healthy organs and tissue FR-expression is restricted to only a few sites such as for instance the kidneys. This demonstrates why FR-targeting is an attractive strategy for the development of new therapy concepts. Due to its high FR-binding affinity (KD < 10-9 M) the vitamin folic acid has emerged as an almost ideal targeting agent. Therefore, a variety of folic acid radioconjugates for nuclear imaging have been developed. However, in spite of the large number of cancer patients who could benefit of a folate-based radionuclide therapy, a therapeutic concept with folate radioconjugates has not yet been envisaged for clinical application. The reason is the generally high accumulation of folate radioconjugates in the kidneys where emission of particle-radiation may result in damage to the renal tissue. Therefore, the design of more sophisticated folate radioconjugates providing improved tissue distribution profiles are needed. This review article summarizes recent developments with regard to a therapeutic application of folate radioconjugates. A new construct of a folate radioconjugate and an application protocol which makes use of a pharmacological interaction allowed the first preclinical therapy experiments with radiofolates. These results raise hope for future application of such new concepts also in the clinic.Keywords
This publication has 92 references indexed in Scilit:
- In Vitro and in Vivo Evaluation of an Innocuous Drug Cocktail To Improve the Quality of Folic Acid Targeted Nuclear Imaging in Preclinical ResearchMolecular Pharmaceutics, 2013
- Folic Acid Conjugates for Nuclear Imaging of Folate Receptor–Positive CancerJournal of Nuclear Medicine, 2010
- Strategy to Prevent Drug-Related Hypersensitivity in Folate-Targeted Hapten Immunotherapy of CancerThe AAPS Journal, 2009
- Antimetabolite RadiosensitizersJournal of Clinical Oncology, 2007
- Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneysNuclear Medicine and Biology, 2007
- Folate receptor overexpression is associated with poor outcome in breast cancerInternational Journal of Cancer, 2007
- Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.2005
- Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid TumorsThe Oncologist, 2001
- Folate receptor type ? is a neutrophilic lineage marker and is differentially expressed in myeloid leukemiaCancer, 1999
- Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.1993